AlzeCure Pharma

Activities: Drug Delivery Research & Development

Trending Articles

  1. From data to decisions: applying criticality and failure probability in process risk mitigation This article presents an exploration of how structured, data-based methods enhance quality control, optimise specifications and improve process robustness throughout the...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Stop reviewing good data: review‑by‑exception for chromatography QC Labs spend hours confirming routine chromatograms while real risks hide in plain sight; regulators support a better path if data are captured and surfaced correctly, notes...
  3. SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the...
  4. Manufacturing Chemist Stand Side with GEA and Hovione We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  5. Vileda Professional CE launches revolutionary single-use microfibre mopping system Vileda Professional CE launches revolutionary single-use microfibre mopping system for cleanrooms and controlled environments

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Regulatory

AlzeCure's topical pain gel gets into the FDA good books following Phase II trial

The FDA has stated its positive opinion on a preIND application submitted ahead of AlzeCure's Orphan Drug Designation application
Training & Education

AlzeCure releases paper on Trk receptor modulation for Alzheimer's disease

The paper details the potential of Trk receptor modulation in treating neurological conditions such as Alzheimer's and Parkinson's disease
Research & Development

AlzeCure elect Dr Jan Lundberg as a new board member

Dr Lundberg has experience in leadership position in global pharmaceutical companies, including AstraZeneca and Eli Lilly

AlzeCure's Alzheimer's project NeuroRestore ACD856 granted an additional patent

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF and NGF
Manufacturing

AlzeCure Pharma receives patent for anti-Alzheimer's drug

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain
Subscribe now